Solid Biosciences receives $50M investment!
31 Mar 2017
Exciting news as Solid Biosciences receives $50M investment on Thursday led by RA Capital Management and Bain Capital's new life sciences fund.
"The announcement marks the first investment closed by Bain Capital Life Sciences, a recently-formed fund, led by former Biogen executive Adam Koppel. Solid is developing gene therapy treatments for Duchenne muscular dystrophy. One of several biotechs focused on Duchenne, Ilan Ganot launched Solid after his son was diagnosed with Duchenne. "Solid is hoping to use gene therapy technology to insert a corrected version of the dystrophin gene. Solid said that it planned to use the $50 million investment to advance its lead drug into the clinic in the second half of this year, and to boost its manufacturing capabilities." - Boston Business Journal, Mar 30, 2017, 9:54am EDT.
To read the full story: http://www.bizjournals.com/boston/news/2017/03/30/biogen-backed-duchenne-firm-solid-biosciences.html
COPYRIGHT 2014 HARRISON’S FUND
ALL RIGHTS RESERVED | REGISTERED UK CHARITY NO. 1146662
SITE BY MZURI DESIGN